Phio Pharmaceuticals Corp. (PHIO) Stock Price, Financials & Summary

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$0.88

From 52W high−46.36%

Volume34164.00

Market cap$10.28M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataNov 4, 2026

Open

$0.88

From 52W high

−46.36%

Volume

34164.00

Market cap

$10.28M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

0.2x

P/E (TTM)

—

RSI (14)

45.5

MomentumView details →

1D Return

−1.99%

YTD Return

−14.30%

SummaryUpdated Jun 1, 2026

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage biotechnology company founded in 2011 and headquartered in Marlborough, Massachusetts. Originally incorporated as RXi Pharmaceuticals Corporation, the company rebranded to its current name in November 2018. Phio specializes in developing immuno-oncology therapeutics using its proprietary INTASYL platform, which focuses on enhancing the body's immune system to fight cancer through innovative gene regulation techniques.

Ask drillr about Phio Pharmaceuticals Corp. →

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

0.2x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

0.8x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−102.40%

ROA (TTM)

−90.19%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

+100.00%

FCF YoY

−70.87%

Revenue CAGR 3Y

—

EPS CAGR 3Y

−59.34%

EBITDA YoY

−82.21%

MomentumView details →

1D Return

−1.99%

YTD Return

−14.30%

1Y Return

−43.04%

RSI (14)

45.5

vs 50D SMA

−8.66%

vs 200D SMA

−17.02%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

15.87x

Quick Ratio

15.87x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$0.36

EPS Surprise

0.00%

Beats (12Q)

6/12

Next Q EPS Est

−$0.39

Avg Surprise (4Q)

4.11%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−12.90M

Op. CF (TTM)

−12.20M

Next earningsNov 12, 2026 →

Latest newsMore news →

Phio Pharmaceuticals announced successful completion of its first commercial-scale cGMP batch of PH-762 drug substance.22d ago

Phio Pharmaceuticals announced it accepted an invitation to present its INTASYL siRNA therapeutic platform and PH-762 program update at the National Investment Banking Association's 153rd Conference on October 6-7, 2026, in Fort Lauderdale, Florida.30d ago

Similar companies

enGene Holdings Inc. WarrantsENGNW Aspire Biopharma Holdings, Inc.ASBP CytoMed Therapeutics LimitedGDTC Anebulo Pharmaceuticals, Inc.ANEB SeaStar Medical Holding CorporationICU BioVie Inc.BIVI Find similar companies →

Latest newsMore news →

Phio Pharmaceuticals announced successful completion of its first commercial-scale cGMP batch of PH-762 drug substance.22d ago Phio Pharmaceuticals announced it accepted an invitation to present its INTASYL siRNA therapeutic platform and PH-762 program update at the National Investment Banking Association's 153rd Conference on October 6-7, 2026, in Fort Lauderdale, Florida.30d ago Phio Pharmaceuticals Corp. appointed Robert J. Bitterman as President & Chief Executive Officer.37d ago